References
- Nolvadex Adjuvant Trial Organisation (NATO). Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. Lancet 1983; 450
- Nolvadex Adjuvant Trial Organisation (NATO). Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Analysis at eight years. Adjuvant Trial Organisation. Br J Cancer 1988; 57: 608–11
- Adjuvant tamoxifen in the management of operable breast cancer. The Scottish trial. Report from the Breast Cancer Trials Comittee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet. 1987; 171–5
- Henderson I C, Mouridsen H. Early breast cancer trialists' collaborative group (EBCTCG). Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28896 women. N Engl J Med 1988; 319: 1681–92
- Consensus Conference. National Institute of Health. Adjuvant therapy for breast cancer. JAMA 1985; 254: 3461–3
- Cancer mammae. Primary treatment. Norwegian Cancer Society. Norwegian Surgical Association1st edition. Oslo 1981
- Cancer mammae. Primary treatment. Norwegian Cancer Society. Norwegian Surgical Association. Norwegian Association of Therapeutic Oncology2nd edition. Oslo 1988
- Raabe N K, Fosså S D. Primary invasive breast carcinoma in Oslo 1980–89. Incidence and delay. Acta Oncol 1996; 35: 9–15
- Gundersen S, Hannisdal E, Søreide J A, Skarstein A, Varhaug J E. Adjuvant tamoxifen for pre- and postmenopausal women with estrogen receptor positive, node positive breast cancer: A randomized study. Breast Cancer Res Treat 1995; 36: 49–53
- Cody H S, Laughlin E H, Trillo C, Urban J A. Have changing treatment patterns affected outcome for operable breast cancer? Ten-year follow-up in 1288 patients. 1965 to. 1978. Ann Surg 1991; 213: 297–307
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Early breast cancer trialists' collaborative group. Lancet. 1992; 339: 1–15
- Ovarian ablation in early breast cancer: An overview of the randomised trials. Early breast cancer trialist's collaborative group. Lancet. 1996, in press
- Carbone P. Adjuvant therapy of stage II breast cancer. Cancer 1990; 65: 2148–54
- Auquier A, Rutqvist L E, Hpst H, Rotstein S, Arriagda R. Post-mastectomy megavoltage radiotherapy: The Oslo and Stockholm trials. Eur J Cancer 1992; 28: 433–7
- Effects of radiotherapy and surgery in early breast cancer. Early breast cancer trialists' collaborative group. N Engl J Med. 1995; 333: 1444–55
- Rutqvist L E, Cedermark B, Glas U, et al. Randomized trial of adjuvant tamoxifen in node negative postmenopausal breast cancer. Acta Oncol 1992; 312: L265–70
- Cummings F J, Gray R, Tormey D C, et al. Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: Long-term follow-up and causes of death. J Clin Oncol 1993; 11: 29–35
- Fornander T, Rutqvist L E, Cedermark B, et al. Adjuvant tamoxifen in early-stage breast cancer: Effect on intercurrent morbidity and mortality. J Clin Oncol 1991; 9: 1740–8
- Hand R, Sener S, Imperato J, Chmiel J S, Sylvester J A, Fremgen A. Hospital variables associated with quality of care for breast cancer patients. JAMA 1991; 266: 3429–32